Lv8
8190 积分 2020-10-11 加入
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
8小时前
已完结
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
[Breast cancer treatment guidelines(2022 edition)]
4个月前
已完结
Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer
4个月前
已完结
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
4个月前
已完结
Final Survival Results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy – PENELOPE-B
4个月前
已完结
Reply to Letter to the Editor “Final results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2− breast cancer and residual disease after neoadjuvant chemotherapy—PENELOPE-B” by Sahin and Guven
4个月前
已完结
Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study
4个月前
已完结
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer
5个月前
已完结
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial
7个月前
已完结
皖公网安备34019202002308
